Anebulo Pharmaceuticals, Inc.

NASDAQ•ANEB

CEO: Dr. Joseph F. Lawler M.D., Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-05-07

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.

Contact Information

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, 78734, United States

512-598-0931

www.anebulo.com

Market Cap

$22.43M

P/E (TTM)

-2.8

17.9

Dividend Yield

52W High

$3.42

52W Low

$0.30

52W Range

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q2 2026 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.05+0.00%

4-Quarter Trend

FCF

-$1.31M+0.00%

4-Quarter Trend

2026 Q2 Earnings Highlights

Key Highlights

Six Month Net Loss Reduced Six month net loss decreased to $(4.158M) USD, reflecting $506K improvement against prior period results.

R&D Spending Decreased Six month R&D expenses fell $561K USD to $1.975M, due to lower contract manufacturing activities.

Cash Position Maintained Cash and equivalents stood at $9.042M USD as of December 31, 2025, following operating cash usage.

Financing Provided Cash Inflow Financing activities provided $15.0M USD cash inflow, supporting operations before the reporting period end date.

Risk Factors

Future Funding Dependency Expect continued operating losses; cash runway estimated for 12 months requiring future capital raises.

Clinical Trial Uncertainty Success hinges on favorable clinical trial results and obtaining necessary regulatory approvals for product candidates.

Going Private Liquidity Risk Plan to delist from Nasdaq; reduced public information availability may increase stock illiquidity and volatility.

Equity Dilution Risk Future equity financing or Loan Agreement stock issuance will cause substantial dilution to existing common stockholders.

Outlook

Prioritizing Pediatric IV Formulation Prioritizing intravenous formulation development for pediatric indication, seeking faster regulatory pathway for emergency treatment.

IV Study Currently Ongoing Initiated ongoing single ascending dose study for IV selonabant in healthy adults during third quarter 2025.

Government Operations Disruption Risk Future government shutdowns pose risk to timely regulatory reviews, grant disbursements, and clinical trial oversight.

G&A Expenses Expected Decline General administrative expenses expected to decrease following completion of planned deregistration from SEC reporting.

Peer Comparison

Revenue (TTM)

MGNX

$149.50M

+0.8%

ZNTL

$26.87M

-33.8%

SRZN

$3.60M

-64.0%

Gross Margin (Latest Quarter)

SRZN

100.0%

+0.0pp

MGNX

62.4%

+19.9pp

ANEB

0.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
SRZN	$216.09M	-2.5	-4404.2%	7.5%
ZNTL	$195.80M	-1.3	-51.5%	11.2%
MGNX	$189.78M	-2.5	-120.2%	41.6%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 7, 2026

EPS:-$0.14

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data